Flask Data

Company Overview

Snapshot

Founded in March 2014 by Danny Lieberman and Jenya Konikov-Rozenman, Flask Data operates with 1–10 employees. The company focuses on real-time data collection for clinical trials and was acquired in February 2024.

Business overview

Flask Data provides a cloud platform for the real-time collection of clinical data, utilizing AI-driven detection and response to protocol compliance issues. Its Flaskdata.io automation platform aims to shorten clinical trial completion times for life sciences companies by delivering interpretable data in near real-time. The platform's API supports digital therapeutics, digital health, medical device, and mobile application developers by streaming and retrieving clinical data at high rates, while maintaining HIPAA, GDPR, and 21 CFR Part 11 compliance. The company operates within the Health Tech & Life Sciences sector, specifically in Digital Healthcare and Clinical Workflow.

Strategic signal

In February 2024, Flask Data became non-active due to an acquisition, signaling a strategic exit for the company. This development indicates a successful culmination of its efforts in clinical trial data automation and compliance, suggesting its technology and market position were attractive to an acquiring entity. For investors, this highlights the potential for M&A activity within the Health Tech & Life Sciences sector for companies offering specialized, compliant data solutions.

Company Intelligence Q&A

When was Flask Data founded and by whom?

Flask Data was founded in March 2014 by Danny Lieberman and Jenya Konikov-Rozenman.

What is the status of Flask Data?

Flask Data became non-active in February 2024 due to an acquisition.

What compliance standards does Flask Data's platform meet?

The Flaskdata.io platform is HIPAA, GDPR, and 21 CFR Part 11 compliant, ensuring secure and regulated data handling for clinical trials.

How does Flask Data's technology benefit clinical trials?

Flask Data's automation platform helps life sciences companies obtain interpretable data in near real-time, which can shorten clinical trial completion times by three to six months.